Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,036,888
  • Shares Outstanding, K 106,017
  • Annual Sales, $ 464,370 K
  • Annual Income, $ -139,670 K
  • EBIT $ -122 M
  • EBITDA $ -129 M
  • 60-Month Beta 0.95
  • Price/Sales 19.18
  • Price/Cash Flow N/A
  • Price/Book 7.78

Options Overview Details

View History
  • Implied Volatility 36.84% ( +0.47%)
  • Historical Volatility 25.18%
  • IV Percentile 35%
  • IV Rank 12.16%
  • IV High 115.58% on 04/15/24
  • IV Low 25.94% on 11/18/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 8
  • Volume Avg (30-Day) 165
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 5,262
  • Open Int (30-Day) 8,768

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 7
  • High Estimate 0.22
  • Low Estimate -0.16
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.37 +5.27%
on 12/11/24
89.12 -3.88%
on 12/18/24
-0.77 (-0.89%)
since 11/26/24
3-Month
70.90 +20.82%
on 10/07/24
93.45 -8.34%
on 11/11/24
+12.45 (+17.01%)
since 09/26/24
52-Week
62.78 +36.44%
on 02/22/24
93.45 -8.34%
on 11/11/24
+14.38 (+20.17%)
since 12/26/23

Most Recent Stories

More News
Intra-Cellular Therapies Presents New Efficacy and Safety Data for CAPLYTA in Major Depressive Disorder at ACNP Annual Meeting

Intra-Cellular Therapies presents new data on CAPLYTA's efficacy and safety in treating major depressive disorder at ACNP conference.Quiver AI SummaryIntra-Cellular Therapies, Inc. presented new data on...

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

ITCI : 85.64 (+0.47%)
Insider Sale: Chairman and CEO of $ITCI (ITCI) Sells 1,534 Shares

Sharon Mates, the Chairman and CEO of $ITCI ($ITCI), sold 1,534 shares of the company on 12-05-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.1% of their...

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies Submits Supplemental New Drug Application for CAPLYTA as Adjunctive Therapy in Major Depressive Disorder

Intra-Cellular Therapies submitted an sNDA for CAPLYTA to treat Major Depressive Disorder, demonstrating efficacy and safety.Quiver AI SummaryIntra-Cellular Therapies, Inc. announced the submission of...

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

ITCI : 85.64 (+0.47%)
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

ITCI : 85.64 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 88.51
2nd Resistance Point 87.15
1st Resistance Point 86.19
Last Price 85.64
1st Support Level 83.87
2nd Support Level 82.51
3rd Support Level 81.55

See More

52-Week High 93.45
Last Price 85.64
Fibonacci 61.8% 81.73
Fibonacci 50% 78.11
Fibonacci 38.2% 74.50
52-Week Low 62.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar